Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews-Reference-Cited by-同舟云学术

Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews

Published:2020-08-24 Issue:6 Volume:4 Page:
ISSN:2515-5091
Container-title:JNCI Cancer Spectrum
language:en
Short-container-title:

Author:

Van Leeuwen Marina T¹^ORCID,Luu Steven¹,Gurney Howard²,Brown Martin R²,Pearson Sallie-Anne¹,Webber Kate³⁴,Hunt Lee⁵,Hong Soojung¹⁶^ORCID,Delaney Geoffrey P⁷⁸⁹,Vajdic Claire M¹^ORCID

Affiliation:

1. Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia

2. Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia

3. Department of Oncology, Monash Health, Clayton, Victoria, Australia

4. School of Clinical Sciences, Monash University, Clayton, Victoria, Australia

5. Cancer Voices NSW, Milsons Point, New South Wales, Australia

6. Division of Oncology-Haematology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea

7. Liverpool Cancer Therapy Centre, Liverpool, New South Wales, Australia

8. Collaboration for Cancer Outcomes Research and Evaluation, Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia

9. South Western Sydney Clinical School, University of New South Wales, Liverpool, New South Wales, Australia

Abstract

Abstract Background Several targeted therapies for cancer have been associated with cardiovascular toxicity. The evidence for this association has not been synthesized systematically nor has the quality of evidence been considered. We synthesized systematic review evidence of cardiovascular toxicity of individual targeted agents. Methods We searched MEDLINE, Embase, and the Cochrane Database of Systematic Reviews for systematic reviews with meta-analyses of cardiovascular outcomes for individual agents published to May 2020. We selected reviews according to prespecified eligibility criteria (International Prospective Register of Systematic Reviews CRD42017080014). We classified evidence of cardiovascular toxicity as sufficient, probable, possible, or indeterminate for specific cardiovascular outcomes based on statistical significance, study quality, and size. Results From 113 systematic reviews, we found at least probable systematic review evidence of cardiovascular toxicity for 18 agents, including high- and all-grade hypertension for bevacizumab, ramucirumab, axitinib, cediranib, pazopanib, sorafenib, sunitinib, vandetanib, aflibercept, abiraterone, and enzalutamide, and all-grade hypertension for nintedanib; high- and all-grade arterial thromboembolism (includes cardiac and/or cerebral events) for bevacizumab and abiraterone, high-grade arterial thromboembolism for trastuzumab, and all-grade arterial thromboembolism for sorafenib and tamoxifen; high- and all-grade venous thromboembolism (VTE) for lenalidomide and thalidomide, high-grade VTE for cetuximab and panitumumab, and all-grade VTE for bevacizumab; high- and all-grade left ventricular ejection fraction decline or congestive heart failure for bevacizumab and trastuzumab, and all-grade left ventricular ejection fraction decline/congestive heart failure for pazopanib and sunitinib; and all-grade corrected QT interval prolongation for vandetanib. Conclusions Our review provides an accessible summary of the cardiovascular toxicity of targeted therapy to assist clinicians and patients when managing cardiovascular health.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jncics/advance-article-pdf/doi/10.1093/jncics/pkaa076/33678209/pkaa076.pdf

Reference209 articles.

1. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors;Li;J Am Coll Cardiol,2015

2. Cardio-oncology—strategies for management of cancer-therapy related cardiovascular disease;Totzeck;Int J Cardiol,2019

3. Oncocardiology—past, present, and future: a review;Yeh;JAMA Cardiol,2016

4. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach;Aromataris;Int J Evid Based Healthc,2015

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NETWORK TOXICOLOGY FOR THE CARDIOVASCULAR TOXICITY ANALYSIS OF TYROSINE KINASE INHIBITORS;Ankara Universitesi Eczacilik Fakultesi Dergisi;2024-07-24

2. Exudative pleural effusion during sunitinib treatment;BMJ Case Reports;2024-06

3. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications;Drug Design, Development and Therapy;2024-03

4. Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors;Internal Medicine;2024

5. Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: a population-based cohort study;The Lancet Regional Health - Western Pacific;2023-10